{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:07:38Z","timestamp":1793768858757,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Open Research Fund of Hubei Province Key Laboratory of Precision Radiation Oncology","award":["2025ZLJZFL008"],"award-info":[{"award-number":["2025ZLJZFL008"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471184"],"award-info":[{"award-number":["82471184"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2023AFB1060"],"award-info":[{"award-number":["2023AFB1060"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-026-02850-9","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T16:07:01Z","timestamp":1778342821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Should standard concurrent chemoradiotherapy remain the preferred treatment for elderly patients with locoregionally advanced nasopharyngeal carcinoma?"],"prefix":"10.1186","volume":"21","author":[{"given":"Shuhan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaojuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"10192","key":"2850_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64\u201380.","journal-title":"Lancet"},{"issue":"6","key":"2850_CR2","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"2850_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","volume":"18","author":"KCW Wong","year":"2021","unstructured":"Wong KCW, Hui EP, Lo KW, Lam WKJ, Johnson D, Li L, et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol. 2021;18(11):679\u201395.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2850_CR4","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","volume":"16","author":"M Al-Sarraf","year":"1998","unstructured":"Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16(4):1310\u20137.","journal-title":"J Clin Oncol"},{"key":"2850_CR5","first-page":"59","volume":"32","author":"P Blanchard","year":"2022","unstructured":"Blanchard P, Lee AWM, Carmel A, Wai Tong N, Ma J, Chan ATC, et al. Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients. Clin Transl Radiat Oncol. 2022;32:59\u201368.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"11","key":"2850_CR6","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509\u201320.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2850_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ijc.32099","volume":"145","author":"WF Li","year":"2019","unstructured":"Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, et al. Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial. Int J Cancer. 2019;145(1):295\u2013305.","journal-title":"Int J Cancer"},{"issue":"6","key":"2850_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","volume":"16","author":"P Blanchard","year":"2015","unstructured":"Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16(6):645\u201355.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2850_CR9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1470-2045(23)00163-8","volume":"24","author":"C Petit","year":"2023","unstructured":"Petit C, Lee A, Ma J, Lacas B, Ng WT, Chan ATC, et al. Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis. Lancet Oncol. 2023;24(6):611\u201323.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2850_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.oraloncology.2011.08.019","volume":"48","author":"HC Sze","year":"2012","unstructured":"Sze HC, Ng WT, Chan OS, Shum TC, Chan LL, Lee AW. Radical radiotherapy for nasopharyngeal carcinoma in elderly patients: the importance of co-morbidity assessment. Oral Oncol. 2012;48(2):162\u20137.","journal-title":"Oral Oncol"},{"key":"2850_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","volume":"156","author":"B Lacas","year":"2021","unstructured":"Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021;156:281\u201393.","journal-title":"Radiother Oncol"},{"issue":"7","key":"2850_CR12","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s00405-020-06399-5","volume":"278","author":"Y Lyu","year":"2021","unstructured":"Lyu Y, Ni M, Zhai R, Kong F, Du C, Hu C, et al. Clinical characteristics and prognosis of elderly nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. Eur Arch Otorhinolaryngol. 2021;278(7):2549\u201357.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"3","key":"2850_CR13","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s00066-019-01533-7","volume":"196","author":"JL Mi","year":"2020","unstructured":"Mi JL, Meng YL, Wu HL, Cao YL, Zhang B, Pan YF, et al. Comparison of intensity-modulated radiation therapy alone vs. intensity-modulated radiation therapy combined with chemotherapy in elderly nasopharyngeal carcinoma patients (aged\u2009>\u200965 years). Strahlenther Onkol. 2020;196(3):270\u20139.","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"2850_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s12885-016-2661-y","volume":"16","author":"Q Zeng","year":"2016","unstructured":"Zeng Q, Wang J, Lv X, Li J, Yin LJ, Xiang YQ, et al. Induction Chemotherapy Followed by Radiotherapy versus Concurrent Chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: finding from a propensity-matched analysis. BMC Cancer. 2016;16(1):693.","journal-title":"BMC Cancer"},{"issue":"17","key":"2850_CR15","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.7150\/jca.26145","volume":"9","author":"Q Yang","year":"2018","unstructured":"Yang Q, Zhao TT, Qiang MY, Hu L, Lv X, Ye YF, et al. Concurrent Chemoradiotherapy versus Intensity-modulated Radiotherapy Alone for Elderly Nasopharyngeal Carcinoma Patients with Pre-treatment Epstein-Barr Virus DNA: A Cohort Study in an Endemic Area with Long-term Follow-up. J Cancer. 2018;9(17):3023\u201331.","journal-title":"J Cancer"},{"issue":"8","key":"2850_CR16","doi-asserted-by":"publisher","first-page":"101648","DOI":"10.1016\/j.jgo.2023.101648","volume":"14","author":"J Chen","year":"2023","unstructured":"Chen J, Ding J, Xu Y, Hong H, Lin X, Xu M, et al. Significance of chemotherapy for older patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A propensity score matching analysis. J Geriatr Oncol. 2023;14(8):101648.","journal-title":"J Geriatr Oncol"},{"key":"2850_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1748-717X-8-70","volume":"8","author":"H Liu","year":"2013","unstructured":"Liu H, Chen QY, Guo L, Tang LQ, Mo HY, Zhong ZL, et al. Feasibility and efficacy of chemoradiotherapy for elderly patients with locoregionally advanced nasopharyngeal carcinoma: results from a matched cohort analysis. Radiat Oncol. 2013;8:70.","journal-title":"Radiat Oncol"},{"issue":"3","key":"2850_CR18","doi-asserted-by":"publisher","first-page":"e0119593","DOI":"10.1371\/journal.pone.0119593","volume":"10","author":"Q Zeng","year":"2015","unstructured":"Zeng Q, Xiang YQ, Wu PH, Lv X, Qian CN, Guo X. A matched cohort study of standard chemo-radiotherapy versus radiotherapy alone in elderly nasopharyngeal carcinoma patients. PLoS ONE. 2015;10(3):e0119593.","journal-title":"PLoS ONE"},{"key":"2850_CR19","doi-asserted-by":"publisher","first-page":"110081","DOI":"10.1016\/j.radonc.2024.110081","volume":"191","author":"F Wang","year":"2024","unstructured":"Wang F, Zhou L, Zhang LJ, Xie CB, Liao ZW, Lin XD, et al. Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II nasopharyngeal carcinoma after intensity-modulated radiotherapy: A propensity score-matched cohort study. Radiother Oncol. 2024;191:110081.","journal-title":"Radiother Oncol"},{"key":"2850_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.oraloncology.2017.08.006","volume":"73","author":"SG Wu","year":"2017","unstructured":"Wu SG, Liao XL, He ZY, Tang LY, Chen XT, Wang Y, et al. Demographic and clinicopathological characteristics of nasopharyngeal carcinoma and survival outcomes according to age at diagnosis: A population-based analysis. Oral Oncol. 2017;73:83\u20137.","journal-title":"Oral Oncol"},{"issue":"19","key":"2850_CR21","doi-asserted-by":"publisher","first-page":"19523","DOI":"10.1002\/cam4.6562","volume":"12","author":"G Yang","year":"2023","unstructured":"Yang G, Huang J, Sun J, Wang L. Elderly nasopharyngeal carcinoma patients (aged\u2009\u2265\u200970 years): Survival and treatment strategies. Cancer Med. 2023;12(19):19523\u20139.","journal-title":"Cancer Med"},{"issue":"2","key":"2850_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.tranon.2018.01.013","volume":"11","author":"F Wang","year":"2018","unstructured":"Wang F, Jiang C, Ye Z, Sun Q, Liu T, Xu M, et al. Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With Nasopharyngeal Carcinoma. Transl Oncol. 2018;11(2):338\u201345.","journal-title":"Transl Oncol"},{"issue":"1","key":"2850_CR23","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1186\/s12885-016-2974-x","volume":"16","author":"HM Li","year":"2016","unstructured":"Li HM, Li P, Qian YJ, Wu X, Xie L, Wang F, et al. A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma. BMC Cancer. 2016;16(1):946.","journal-title":"BMC Cancer"},{"issue":"1","key":"2850_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40880-019-0380-x","volume":"39","author":"JF Liao","year":"2019","unstructured":"Liao JF, Zhang Q, Du XJ, Lan M, Liu S, Xia YF, et al. Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis. Cancer Commun (Lond). 2019;39(1):40.","journal-title":"Cancer Commun (Lond)"},{"issue":"8","key":"2850_CR25","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1111\/cas.16213","volume":"115","author":"C Cao","year":"2024","unstructured":"Cao C, Fang Y, Jiang F, Jin Q, Jin T, Huang S, et al. Concurrent nimotuzumab and intensity-modulated radiotherapy for elderly patients with locally advanced nasopharyngeal carcinoma. Cancer Sci. 2024;115(8):2729\u201337.","journal-title":"Cancer Sci"},{"issue":"5","key":"2850_CR26","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ejca.2010.10.026","volume":"47","author":"AW Lee","year":"2011","unstructured":"Lee AW, Tung SY, Ngan RK, Chappell R, Chua DT, Lu TX, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur J Cancer. 2011;47(5):656\u201366.","journal-title":"Eur J Cancer"},{"issue":"11","key":"2850_CR27","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1634\/theoncologist.2016-0105","volume":"21","author":"H Peng","year":"2016","unstructured":"Peng H, Chen L, Zhang Y, Li WF, Mao YP, Zhang F, et al. Prognostic Value of the Cumulative Cisplatin Dose During Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Secondary Analysis of a Prospective Phase III Clinical Trial. Oncologist. 2016;21(11):1369\u201376.","journal-title":"Oncologist"},{"issue":"12","key":"2850_CR28","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019;381(12):1124\u201335.","journal-title":"N Engl J Med"},{"issue":"33","key":"2850_CR29","doi-asserted-by":"publisher","first-page":"8461","DOI":"10.1200\/JCO.2004.00.3863","volume":"23","author":"L Zhang","year":"2005","unstructured":"Zhang L, Zhao C, Peng PJ, Lu LX, Huang PY, Han F, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol. 2005;23(33):8461\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2850_CR30","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/cas.13589","volume":"109","author":"H Peng","year":"2018","unstructured":"Peng H, Tang LL, Liu X, Chen L, Li WF, Mao YP, et al. Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Cancer Sci. 2018;109(5):1609\u201316.","journal-title":"Cancer Sci"},{"issue":"12","key":"2850_CR31","doi-asserted-by":"publisher","first-page":"e2138470","DOI":"10.1001\/jamanetworkopen.2021.38470","volume":"4","author":"QN Tang","year":"2021","unstructured":"Tang QN, Liu LT, Qi B, Guo SS, Luo DH, Sun R, et al. Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2021;4(12):e2138470.","journal-title":"JAMA Netw Open"},{"issue":"13","key":"2850_CR32","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.ejca.2015.05.025","volume":"51","author":"PY Huang","year":"2015","unstructured":"Huang PY, Zeng Q, Cao KJ, Guo X, Guo L, Mo HY, et al. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area. Eur J Cancer. 2015;51(13):1760\u201370.","journal-title":"Eur J Cancer"},{"issue":"5","key":"2850_CR33","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(21)00075-9","volume":"22","author":"X Lv","year":"2021","unstructured":"Lv X, Cao X, Xia WX, Liu KY, Qiang MY, Guo L, et al. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):716\u201326.","journal-title":"Lancet Oncol"},{"key":"2850_CR34","doi-asserted-by":"publisher","first-page":"101797","DOI":"10.1016\/j.tranon.2023.101797","volume":"39","author":"X Niu","year":"2024","unstructured":"Niu X, Liu P, Zhou X, Ou D, Wang X, Hu C. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with chemoradiotherapy for induction chemotherapy resistant locally advanced nasopharyngeal carcinoma: A prospective phase II study. Transl Oncol. 2024;39:101797.","journal-title":"Transl Oncol"},{"key":"2850_CR35","doi-asserted-by":"crossref","unstructured":"Cao C, Fang Y, Jiang F, Jin Q, Jin T, Huang S, et al. Concurrent nimotuzumab and intensity-modulated radiotherapy for elderly patients with locally advanced nasopharyngeal carcinoma. Cancer Sci. 2024.","DOI":"10.1111\/cas.16213"},{"issue":"1","key":"2850_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.tranon.2017.11.002","volume":"11","author":"F Wang","year":"2018","unstructured":"Wang F, Jiang C, Ye Z, Liu T, Sun Q, Yan F, et al. Treatment Outcomes of 257 Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Nimotuzumab Plus Intensity-Modulated Radiotherapy with or without Chemotherapy: A Single-Institution Experience. Transl Oncol. 2018;11(1):65\u201373.","journal-title":"Transl Oncol"},{"issue":"6","key":"2850_CR37","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/ijc.30819","volume":"141","author":"R You","year":"2017","unstructured":"You R, Sun R, Hua YJ, Li CF, Li JB, Zou X, et al. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma. Int J Cancer. 2017;141(6):1265\u201376.","journal-title":"Int J Cancer"},{"issue":"1","key":"2850_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13014-022-02104-4","volume":"17","author":"Y Yin","year":"2022","unstructured":"Yin Y, Zhou Z, Li Z, Shen M, Qin Y, Yang C, et al. Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study. Radiat Oncol. 2022;17(1):135.","journal-title":"Radiat Oncol"},{"issue":"1","key":"2850_CR39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2010.31.3049","volume":"29","author":"L Lee","year":"2011","unstructured":"Lee L, Cheung WY, Atkinson E, Krzyzanowska MK. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J Clin Oncol. 2011;29(1):106\u201317.","journal-title":"J Clin Oncol"},{"issue":"31","key":"2850_CR40","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1200\/JCO.2012.47.7430","volume":"31","author":"S Hoppe","year":"2013","unstructured":"Hoppe S, Rainfray M, Fonck M, Hoppenreys L, Blanc JF, Ceccaldi J, et al. Functional decline in older patients with cancer receiving first-line chemotherapy. J Clin Oncol. 2013;31(31):3877\u201382.","journal-title":"J Clin Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02850-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02850-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02850-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T03:06:05Z","timestamp":1781147165000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02850-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2850"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02850-9","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for this research was obtained from the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Consent to participate was exempted due to the retrospective aspect of the study. This study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, as no identifiable individual data are included in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}